T1	condition 139 157	severe neutropenia
T2	total-participants 511 514	218
T6	outcome 1047 1068	DSN (days) in cycle 1
T7	intervention-participants 1102 1105	101
T8	control-participants 1139 1142	103
T9	outcome 1263 1296	clinically meaningful differences
T10	outcome 1590 1604	adverse events
T5	intervention 14 20	EP2006
T3	eligibility 416 498	breast cancer patients receiving (neo)adjuvant myelosuppressive chemotherapy (TAC)
T12	iv-cont-mean 1073 1077	1.17
T13	iv-cont-sd 1080 1084	1.11
T14	cv-cont-mean 1111 1115	1.20
T15	cv-cont-sd 1118 1122	1.02
T16	control 1124 1133	reference
T4	outcome-Measure 850 901	duration of severe neutropenia (DSN) during cycle 1
T11	outcome 1351 1388	incidence of febrile neutropenia (FN)
T17	outcome 1390 1415	hospitalization due to FN
T18	outcome 1417 1440	incidence of infections
T19	outcome 1442 1497	depth and time of absolute neutrophil count (ANC) nadir
T20	outcome 1502 1522	time to ANC recovery
